TEST BANK k
Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition
k k k k k k k
Author: kTeri kMoser kWoo kand kWendy kL. kWright
, TABLE kOF kCONTENT
Chapter k1. kThe kRole kof kthe kAdvanced kPractice kNurse kas kPrescriber................................................................. 4
Chapter k2. kReview kof kBasic kPrinciples kof kPharmacology .................................................................................. 5
Chapter k3. kRational kDrug kSelection ................................................................................................................... 11
Chapter k4. kLegal kand kProfessional kIssues kin kPrescribing ................................................................................. 14
Chapter k5. kAdverse kDrug kReactions .................................................................................................................. 16
Chapter k6. kAn kIntroduction kto kPharmacogenomics ........................................................................................... 19
Chapter k7. kNutrition kand kNutraceuticals ............................................................................................................ 22
Chapter k8. kHerbal kTherapies .............................................................................................................................. 28
Chapter k9. kCannabis ........................................................................................................................................... 31
Chapter k10. kPharmacoeconomics ....................................................................................................................... 35
Chapter k11. kDrugs kAffecting kthe kAutonomic kNervous kSystem ....................................................................... 38
Chapter k12. kDrugs kAffecting kthe kCentral kNervous kSystem .............................................................................. 45
Chapter k13. kDrugs kAffecting kthe kCardiovascular kand kRenal kSystems ............................................................. 53
Chapter k14. kDrugs kAffecting kthe kRespiratory kSystem ...................................................................................... 61
Chapter k15. kDrugs kAffecting kthe kHematological kSystem ................................................................................. 65
Chapter k16. kDrugs kAffecting kthe kImmune kSystem: kVaccines kand kImmunoglobulins ..................................... 69
Chapter k17. kDrugs kAffecting kthe kImmune kSystem: kImmunomodulators ......................................................... 75
Chapter k18. kDrugs kAffecting kthe kGastrointestinal kSystem ............................................................................... 77
Chapter k19. kDrugs kAffecting kthe kEndocrine kSystem: kPancreatic kHormones kand kAntidiabetic kDrugs ............. 80
Chapter k20. kDrugs kAffecting kthe kEndocrine kSystem: kPituitary, kThyroid, kand kAdrenal kDrugs ....................... 83
Chapter k21. kDrugs kAffecting kthe kReproductive kSystem ................................................................................... 86
Chapter k22. kDrugs kAffecting kthe kBones kand kJoints .......................................................................................... 92
Chapter k23. kDrugs kAffecting kthe kIntegumentary kSystem ................................................................................. 96
Chapter k24. kDrugs kUsed kto kTreat kBacterial kInfections ................................................................................... 101
Chapter k25. kDrugs kUsed kto kTreat kViral, kFungal, kand kProtozoal kInfections................................................... 105
Chapter k26. kDrugs kUsed kto kTreat kInflammatory kProcesses ............................................................................ 108
Chapter k27. kDrugs kUsed kto kTreat kEye kand kEar kDisorders ............................................................................. 111
Chapter k28. kAnemia ......................................................................................................................................... 113
Chapter k29. kAnxiety kand kDepression ............................................................................................................... 116
Chapter k30. kAttention kDeficit-Hyperactivity kDisorder .................................................................................... 120
Chapter k31. kAsthma kand kAllergy ..................................................................................................................... 122
Chapter k32. kChronic kObstructive kPulmonary kDisease .................................................................................... 125
Chapter k33. kContraception ................................................................................................................................ 127
Chapter k34. kCOVID-19: kAcute kand kChronic................................................................................................... 130
Chapter k35. kDermatological kConditions .......................................................................................................... 134
Chapter k36. kDiabetes kManagement .................................................................................................................. 138
Chapter k37. kGastroesophageal kReflux kand kPeptic kUlcer kDisease .................................................................. 146
Chapter k38. kHeadaches ..................................................................................................................................... 149
Chapter k39. kHeart kFailure ................................................................................................................................ 153
Chapter k40. kHIV kDisease kand kAcquired kImmunodeficiency kSyndrome ........................................................ 158
Chapter k41. kMenopausal kHormone kTherapy ................................................................................................... 161
,Chapter k42. kHyperlipidemia ............................................................................................................................. 164
Chapter k43. kHypertension ................................................................................................................................. 169
Chapter k44. kHyperthyroidism kand kHypothyroidism ........................................................................................ 174
Chapter k45. kObesity .......................................................................................................................................... 177
Chapter k46. kPain kManagement: kAcute kand kChronic kPain .............................................................................. 181
Chapter k47. kPneumonia .................................................................................................................................... 185
Chapter k48. kSexually kTransmitted kDiseases kand kVaginitis ............................................................................. 187
Chapter k49. kSubstance kUse kDisorders ............................................................................................................. 190
Chapter k50. kTuberculosis .................................................................................................................................. 195
Chapter k51. kUpper kRespiratory kTract kInfection, kPharyngitis, kSinusitis, kOtitis kMedia, kand kOtitis kExterna .... 197
Chapter k52. kUrinary kTract kInfections .............................................................................................................. 200
Chapter k53. kWomen kas kPatients....................................................................................................................... 203
Chapter k54. kMen kas kPatients ............................................................................................................................ 207
Chapter k55. kPediatric kPatients .......................................................................................................................... 209
Chapter k57. kGeriatric kPatients .......................................................................................................................... 213
, Woo 1
Pharmacotherapeutics kfor kAPN kPrescribers, Ch01
k6e
Chapter k1. kThe kRole kof kthe kAdvanced kPractice kNurse kas kPrescriber
MULTIPLE kCHOICE
1. Nurse kpractitioner kprescriptive kauthority kis kregulated kby:
A. The kNational kCouncil kof kState kBoards kof kNursing
B. The kU.S. kDrug kEnforcement kAdministration
C. The kState kBoard kof kNursing kfor keach kstate
D. The kState kBoard kof kPharmacy
ANS: k C PTS: k k 1
2. The kbenefits kto kthe kpatient kof khaving kan kadvanced kpractice kregistered knurse k(APRN)
prescriber kinclude:
k
A. Nurses kknow kmore kabout kpharmacology kthan kother kprescribers kbecause kthey ktake
kit kboth kin ktheir kbasic knursing kprogram kand kin ktheir kAPRN kprogram.
B. Nurses kcare kfor kthe kpatient kfrom ka kholistic kapproach kand kinclude kthe kpatient
kin kdecision-making kregarding ktheir kcare.
C. APRNs kare kless klikely kto kprescribe knarcotics kand kother kcontrolled ksubstances.
D. APRNs kare kable kto kprescribe kindependently kin kall kstates, kwhereas ka
kphysician’s kassistant kneeds kto khave ka kphysician ksupervising ktheir kpractice.
ANS: k B PTS: k k 1
3. Clinical kjudgment kin kprescribing kincludes:
A. Factoring kin kthe kcost kto kthe kpatient kof kthe kmedication kprescribed
B. Always kprescribing kthe knewest kmedication kavailable kfor kthe kdisease kprocess
C. Handing kout kdrug ksamples kto kpoor kpatients
D. Prescribing kall kgeneric kmedications kto kcut kcosts
ANS: k A PTS: k k 1
4. The kprocess kfor kchoosing kan keffective kdrug kfor ka kdisorder kincludes:
A. Asking kthe kpatient kwhat kdrug kthey kthink kwould kwork kbest kfor kthem
B. Consulting knationally krecognized kguidelines kfor kdisease kmanagement
C. Prescribing kmedications kthat kare kavailable kas ksamples kbefore kwriting ka kprescription
D. Following kU.S. kDrug kEnforcement kAdministration kguidelines kfor kprescribing
ANS: k B PTS: k k 1
5. Nonintentional knonadherence kof kdrug ktherapy kmay koccur kdue kto:
A. Belief kthat kmedication kdoes knot kwork
B. Adverse kdrug kreactions
C. Chronic kconditions kthat krequire kdaily ktherapy
D. Forgetfulness kor kdistraction
ANS: k D PTS: k k 1
Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition
k k k k k k k
Author: kTeri kMoser kWoo kand kWendy kL. kWright
, TABLE kOF kCONTENT
Chapter k1. kThe kRole kof kthe kAdvanced kPractice kNurse kas kPrescriber................................................................. 4
Chapter k2. kReview kof kBasic kPrinciples kof kPharmacology .................................................................................. 5
Chapter k3. kRational kDrug kSelection ................................................................................................................... 11
Chapter k4. kLegal kand kProfessional kIssues kin kPrescribing ................................................................................. 14
Chapter k5. kAdverse kDrug kReactions .................................................................................................................. 16
Chapter k6. kAn kIntroduction kto kPharmacogenomics ........................................................................................... 19
Chapter k7. kNutrition kand kNutraceuticals ............................................................................................................ 22
Chapter k8. kHerbal kTherapies .............................................................................................................................. 28
Chapter k9. kCannabis ........................................................................................................................................... 31
Chapter k10. kPharmacoeconomics ....................................................................................................................... 35
Chapter k11. kDrugs kAffecting kthe kAutonomic kNervous kSystem ....................................................................... 38
Chapter k12. kDrugs kAffecting kthe kCentral kNervous kSystem .............................................................................. 45
Chapter k13. kDrugs kAffecting kthe kCardiovascular kand kRenal kSystems ............................................................. 53
Chapter k14. kDrugs kAffecting kthe kRespiratory kSystem ...................................................................................... 61
Chapter k15. kDrugs kAffecting kthe kHematological kSystem ................................................................................. 65
Chapter k16. kDrugs kAffecting kthe kImmune kSystem: kVaccines kand kImmunoglobulins ..................................... 69
Chapter k17. kDrugs kAffecting kthe kImmune kSystem: kImmunomodulators ......................................................... 75
Chapter k18. kDrugs kAffecting kthe kGastrointestinal kSystem ............................................................................... 77
Chapter k19. kDrugs kAffecting kthe kEndocrine kSystem: kPancreatic kHormones kand kAntidiabetic kDrugs ............. 80
Chapter k20. kDrugs kAffecting kthe kEndocrine kSystem: kPituitary, kThyroid, kand kAdrenal kDrugs ....................... 83
Chapter k21. kDrugs kAffecting kthe kReproductive kSystem ................................................................................... 86
Chapter k22. kDrugs kAffecting kthe kBones kand kJoints .......................................................................................... 92
Chapter k23. kDrugs kAffecting kthe kIntegumentary kSystem ................................................................................. 96
Chapter k24. kDrugs kUsed kto kTreat kBacterial kInfections ................................................................................... 101
Chapter k25. kDrugs kUsed kto kTreat kViral, kFungal, kand kProtozoal kInfections................................................... 105
Chapter k26. kDrugs kUsed kto kTreat kInflammatory kProcesses ............................................................................ 108
Chapter k27. kDrugs kUsed kto kTreat kEye kand kEar kDisorders ............................................................................. 111
Chapter k28. kAnemia ......................................................................................................................................... 113
Chapter k29. kAnxiety kand kDepression ............................................................................................................... 116
Chapter k30. kAttention kDeficit-Hyperactivity kDisorder .................................................................................... 120
Chapter k31. kAsthma kand kAllergy ..................................................................................................................... 122
Chapter k32. kChronic kObstructive kPulmonary kDisease .................................................................................... 125
Chapter k33. kContraception ................................................................................................................................ 127
Chapter k34. kCOVID-19: kAcute kand kChronic................................................................................................... 130
Chapter k35. kDermatological kConditions .......................................................................................................... 134
Chapter k36. kDiabetes kManagement .................................................................................................................. 138
Chapter k37. kGastroesophageal kReflux kand kPeptic kUlcer kDisease .................................................................. 146
Chapter k38. kHeadaches ..................................................................................................................................... 149
Chapter k39. kHeart kFailure ................................................................................................................................ 153
Chapter k40. kHIV kDisease kand kAcquired kImmunodeficiency kSyndrome ........................................................ 158
Chapter k41. kMenopausal kHormone kTherapy ................................................................................................... 161
,Chapter k42. kHyperlipidemia ............................................................................................................................. 164
Chapter k43. kHypertension ................................................................................................................................. 169
Chapter k44. kHyperthyroidism kand kHypothyroidism ........................................................................................ 174
Chapter k45. kObesity .......................................................................................................................................... 177
Chapter k46. kPain kManagement: kAcute kand kChronic kPain .............................................................................. 181
Chapter k47. kPneumonia .................................................................................................................................... 185
Chapter k48. kSexually kTransmitted kDiseases kand kVaginitis ............................................................................. 187
Chapter k49. kSubstance kUse kDisorders ............................................................................................................. 190
Chapter k50. kTuberculosis .................................................................................................................................. 195
Chapter k51. kUpper kRespiratory kTract kInfection, kPharyngitis, kSinusitis, kOtitis kMedia, kand kOtitis kExterna .... 197
Chapter k52. kUrinary kTract kInfections .............................................................................................................. 200
Chapter k53. kWomen kas kPatients....................................................................................................................... 203
Chapter k54. kMen kas kPatients ............................................................................................................................ 207
Chapter k55. kPediatric kPatients .......................................................................................................................... 209
Chapter k57. kGeriatric kPatients .......................................................................................................................... 213
, Woo 1
Pharmacotherapeutics kfor kAPN kPrescribers, Ch01
k6e
Chapter k1. kThe kRole kof kthe kAdvanced kPractice kNurse kas kPrescriber
MULTIPLE kCHOICE
1. Nurse kpractitioner kprescriptive kauthority kis kregulated kby:
A. The kNational kCouncil kof kState kBoards kof kNursing
B. The kU.S. kDrug kEnforcement kAdministration
C. The kState kBoard kof kNursing kfor keach kstate
D. The kState kBoard kof kPharmacy
ANS: k C PTS: k k 1
2. The kbenefits kto kthe kpatient kof khaving kan kadvanced kpractice kregistered knurse k(APRN)
prescriber kinclude:
k
A. Nurses kknow kmore kabout kpharmacology kthan kother kprescribers kbecause kthey ktake
kit kboth kin ktheir kbasic knursing kprogram kand kin ktheir kAPRN kprogram.
B. Nurses kcare kfor kthe kpatient kfrom ka kholistic kapproach kand kinclude kthe kpatient
kin kdecision-making kregarding ktheir kcare.
C. APRNs kare kless klikely kto kprescribe knarcotics kand kother kcontrolled ksubstances.
D. APRNs kare kable kto kprescribe kindependently kin kall kstates, kwhereas ka
kphysician’s kassistant kneeds kto khave ka kphysician ksupervising ktheir kpractice.
ANS: k B PTS: k k 1
3. Clinical kjudgment kin kprescribing kincludes:
A. Factoring kin kthe kcost kto kthe kpatient kof kthe kmedication kprescribed
B. Always kprescribing kthe knewest kmedication kavailable kfor kthe kdisease kprocess
C. Handing kout kdrug ksamples kto kpoor kpatients
D. Prescribing kall kgeneric kmedications kto kcut kcosts
ANS: k A PTS: k k 1
4. The kprocess kfor kchoosing kan keffective kdrug kfor ka kdisorder kincludes:
A. Asking kthe kpatient kwhat kdrug kthey kthink kwould kwork kbest kfor kthem
B. Consulting knationally krecognized kguidelines kfor kdisease kmanagement
C. Prescribing kmedications kthat kare kavailable kas ksamples kbefore kwriting ka kprescription
D. Following kU.S. kDrug kEnforcement kAdministration kguidelines kfor kprescribing
ANS: k B PTS: k k 1
5. Nonintentional knonadherence kof kdrug ktherapy kmay koccur kdue kto:
A. Belief kthat kmedication kdoes knot kwork
B. Adverse kdrug kreactions
C. Chronic kconditions kthat krequire kdaily ktherapy
D. Forgetfulness kor kdistraction
ANS: k D PTS: k k 1
